The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Gathering Around Cancer 2020 | Osimertinib for EGFR-mutant lung cancer

Name: Osimertinib for EGFR-mutant lung cancer
Uploaded: 2020-11-04T00:00:00Z
Duration: 55 s
Description: Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

Jarushka Naidoo • 4 Nov 2020

Gathering Around Cancer 2020

Lung Cancer Non-Small Cell Lung Cancer Osimertinib

FLAURA

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)